Richard Small, CPA

Chief Executive Officer


Mr. Small was promoted to Chief Executive Officer in December, 2017. He was previously Neurotech’s Chief Operating Officer from March 2016 to December 2017 and the Company’s Chief Financial Officer from July 2007 to March, 2016. He has 25 years of both private and public life sciences experience and more than 35 years of overall financial and operational management. He also currently serves as a Trustee, Executive Committee Member and Chairman of the Finance and Business Affairs Committee for the New England College of Optometry. Previously Mr. Small served as Senior Vice President and Chief Financial Officer of Point Therapeutics, a publicly-traded biotechnology company, where he was a founding member of the Company and involved in taking the company public through a reverse merger and in multiple private and public equity offerings. Prior to Point he served as Vice President, Chief Financial Officer at Immulogic Pharmaceutical, Inc., a publicly-traded biotechnology company, where he was involved in multiple licensing deals and several public equity offerings. His early career was spent in senior management positions at Dennison Manufacturing Company and he began his career at the public accounting firm of Coopers and Lybrand, LLC. Mr. Small is a certified public accountant and has a BS in accounting from Northeastern University in Boston, Massachusetts.

Charles Johnson, MD

Chief Medical Officer


Dr Johnson, who was named CMO of Neurotech in March of 2015, is an accomplished physician and pharmaceutical executive with over four decades of experience in clinical practice and the biotech sector. Dr. Johnson was most recently the Vice President of Global Medical Affairs at Vertex. Prior to this, he held leadership positions at Inspire Pharmaceuticals and APT Pharmaceuticals. Notably, during his 13 year tenure at Genentech, he was the Vice President and Head of the Immunology and Tissue Repair clinical group and had responsibility for the approvals of LUCENTIS® for wet age-related macular degeneration and RITUXAN® for rheumatoid arthritis. Prior to joining the pharmaceutical industry, Dr. Johnson spent 18 years practicing medicine. Dr. Johnson received his medical degree from the University of Cape Town in South Africa, attained Board Certification in Pediatrics at the Red Cross War Memorial Children’s Hospital and completed his Pediatric Pulmonology Fellowship at Washington University. He has presented clinical data at numerous medical conferences and published in several respected scientific journals.

Konrad Kauper, MSc

Vice President of Core Technology Development


Konrad Kauper has led the core device development programs for Neurotech’s Encapsulated Cell Technology (ECT) for the past 10 years.  During this period Neurotech has successfully completed several Phase I, Phase II and ex-US clinical trials investigating ECT as a treatment for eye disease including wet macular degeneration, retinitis pigmentosa, dry macular degeneration and macular telangiectasia.  Konrad has over 16 years of experience in biotechnology and pharmaceutical companies having held research and development positions at WR Grace Biomedical, CytoTherapeutics, and Genetics Institute, contributing multiple patents, peer-reviewed scientific articles and oral presentations related to the fields of drug delivery and cell-based therapeutics.   Konrad received his undergraduate and graduate degrees in Chemical Engineering from Northeastern University.

Cahil McGovern, Ph.D.

Vice President of Manufacturing


Dr. McGovern joined Neurotech in 2002 as a Senior Scientist in Process Development and helped develop Encapsulated Cell Technology (ECT) products for the long term treatment of chronic retinal diseases. He brings over 20 years of development, manufacturing, and biological operations experience to his position. He began to oversee the manufacturing operations in 2008 and validated the aseptic manufacturing process employed to manufacture ECT products.   Dr. McGovern has been involved in perfecting the manufacturing process behind all of Neurotech’s ECT products, particularly NT-503 and NT-501. Previously, Dr. McGovern worked in manufacturing and product development at CytoTherapeutics, Inc. He has contributed to scientific articles in the areas of drug delivery and cell-based therapeutics for the treatment of retinal diseases.  Dr. McGovern received his BA and MA degrees from Rhode Island College in Providence, Rhode Island and was awarded his PhD degree from the University of Rhode Island in Kingston, Rhode Island.

Board of Directors



James Mazzo (Chairman)

   • Global President of Ophthalmology, Carl Zeiss Meditec AG


Richard Small, CPA

   • Chief Executive Officer


John Fanning

   • Chief Financial Officer, LFG


David Fuchs

  Chief Investment Officer, LFG




Advisor Group


Thomas Hohman, Ph.D.


·    Former Vice President Retina Translation Medicine: Head of Retinal Disease Drug Discovery at Allergan, Inc


·    Former Vice President Retinal Research and Development at Alcon Research, Ltd.


Neurotech © 2016

News Update

Find out the latest news at Neurotech